O ral anticoagulation medications are commonly prescribed to patients for a variety of conditions. The mainstay of such therapy has been vitamin K antagonists (VKAs), primarily warfarin. The emergence of non-VKA oral anticoagulants, also referred to as novel oral anticoagulants (NOACs) has changed many patients' therapeutic options for anticoagulation. These drugs have proven efficacy in the prevention and management of thrombus, with similar risks of bleeding.
O ral anticoagulation medications are commonly prescribed to patients for a variety of conditions. The mainstay of such therapy has been vitamin K antagonists (VKAs), primarily warfarin. The emergence of non-VKA oral anticoagulants, also referred to as novel oral anticoagulants (NOACs) has changed many patients' therapeutic options for anticoagulation. These drugs have proven efficacy in the prevention and management of thrombus, with similar risks of bleeding.
Patients taking these medications present a unique challenge for clinicians, especially in the performance of invasive procedures and during acute hemorrhage.
Moreover, standard coagulation studies provide an unclear picture of the NOACs' effects. For clinicians, it is important to understand the pharmacologic properties of these agents and their effects on common coagulation tests. In the present review, we cover NOACs' approved use in the United States, pharmacologic properties, and contraindications, along with periprocedural management and treatment strategies for patients with bleeding complications.
Factor Xa Inhibitors
Rivaroxaban Rivaroxaban (Xarelto; Janssen Pharmaceuticals) is an oral direct factor Xa inhibitor. 1 It is approved in the United States for anticoagulation for thrombus prevention in nonvalvular atrial fibrillation (NVAF) and prevention of venous thromboembolism (VTE) in patients undergoing elective total hip or knee arthroplasty. It is also approved for the treatment and reduction of recurrent of deep vein thrombosis and pulmonary embolism. 2 No specific agent is available to reverse its effects.
Non-Vitamin K Antagonist Oral Anticoagulants: The Clinician's New Challenge 613 tion of VTE, including recurrent VTE and VTE after total hip or and total knee arthroplasty. 2 It has the same predictable PD and PK effects as other NOACs, so no routine coagulation monitoring is required. 15 Again, no specific reversal agent is available. 6 Apixaban has a peak plasma concentration at 1 to 3 hours, and its half-life is approximately 12 hours, up to 15 hours in elderly patients. It is metabolized mainly by the liver and excreted in urine and feces. Dose reductions are indicated for patients with NVAF and any 2 of the following criteria: aged 80 years or older, bodyweight less than 60 kg, serum creatinine level more than 1.5 mg/dL, and end-stage renal disease managed with hemodialysis (HD); no dose reduction is required in patients receiving HD who meet none of the other criteria. 6 Mild hepatic impairment requires no dose adjustment, but apixaban should be avoided in patients with moderate to severe hepatic impairment ( Table 2) .
15
When apixaban is administered with a strong dual inhibitor of CYP3A4 and P-gp (ketoconazole, itraconazole, or clarithromycin), a reduced dose of 2.5 mg twice per day is recommended, and patients already receiving a reduced apixaban dose should avoid concomitant use with these agents. Strong dual inducers of CYP3A4 and P-gp (rifampin, carbamazepine, phenytoin, and St John's Wort) decrease the efficacy of the apixaban, and their use should be avoided. 6, 15 Apixaban causes dose-dependent prolongation of PT with varying sensitivity, though to a lesser extent than rivaroxaban. 5 16 Edoxaban is not recommended in Child-Pugh class B or C hepatic impair- Recommendations for when to restart NOACs after procedures with a moderate to high bleeding risk range from 24 to 72 hours after the procedure. The key to restarting NOACs is the certainty that the bleeding risk is controlled. [23] [24] [25] Postoperative bridging should be considered in patients with postoperative ileus or other reasons for prolonged limitation of enteral medications. 23 The NOAC can be restarted 12 hours after the last dose of LMWH. 24 There should be no overlap in the administration of bridging heparin agents and NOACs, given the rapid onset of action for NOACs.
Management of Acute Hemorrhage

General Considerations
Hemorrhage is a difficult complication in patients receiving anticoagulation treatment, and it can be life threatening. The NOACs lack specific reversal agents.
Most current recommendations for managing bleeding complications associated with NOACs stem from small trials involving healthy participants, limited retrospective case series, or expert opinion. [29] [30] [31] The
Perioperative Management
The literature lacks evidence-based recommendations for periprocedural management in patients receiving
NOACs. The suggested guidelines are largely based on expert opinion and case reports. The basic underlying principles driving these guidelines include assessing the risk of bleeding associated with a procedure and understanding the PK effects of these agents ( Table 1) .
For minor procedures not associated with a clinically important bleeding risk, recommendations include discontinuing NOACs 18 to 24 hours before the procedure and restarting them 6 hours later. For elective procedures with minor bleeding risk (eg, hernia repairs, hysterectomy, endoscopy with biopsy, bladder or prostate biopsy), the NOAC should be discontinued at least 24 hours beforehand, allowing 2 elimination half-lives to pass before the procedure in patients with normal elimination. 23 The NOAC treatment should be resumed 24 hours after these low-bleeding-risk procedures. 24 In patients with impaired elimination pathways, clinicians should hold the NOAC for more than 24 hours, especially dabigatran in patients with renal impairment. 23 For procedures associated with a moderate or high risk of bleeding, recommendations include discontinuing NOACs at least 48 hours before the scheduled surgical procedure (approximately ≥3 elimination half-lives). [25] [26] [27] [28] At this point, plasma levels should decrease to less than 15% of initial levels; any longer cessation is unlikely to provide additional hemostatic benefit. Conservative recommendations extend the discontinuation period for 5 days before the procedure, particularly in higher-risk populations (eg, patients with CrCl <50 mL/min or aged >75 years), in which elimination of NOACs can be less predictable and more prolonged. 25 Procedures that in- NOACs. 41 Among available nonspecific reversal agents, limited data suggest that 4FPCC can improve coagulation profiles in patients given NOACs, particularly activated 4FPCC in patients receiving dabigatran. 38, 42, 43 Recombinant factor VIIa is currently approved in the United States to manage and prevent procedure-related bleeding in congenital factor VII deficiencies, hemophilia A or B with inhibitors, and acquired hemophilia. It has a black box warning against use outside those approved situations. 30, 34 Data supporting its use in patients taking NOACs are limited; therefore its use is not clearly indicated. Some advocate it as salvage therapy in lifethreatening situations. 26, 35 However, a review of 35 randomized controlled trials of its off-label use identified a statistically significant increase in the risk of arterial thrombotic events, particularly in elderly patients. 44 
Specific Antidotes
Currently under investigation but not approved by the US Food and Drug Administration are specific antidotes to the NOACs. Idarucizumab, a humanized antibody fragment, is currently in late-phase trials evaluating its
